Drug Trial Radar · NCT07509151
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
420
Planned (sponsor's estimate)
Start
May 5, 2026
Primary completion
Aug 29, 2031
Study completion Apr 5, 2032
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Apr 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the therapeutic benefit and safety of subcutaneous (SC) Surovatamig monotherapy as consolidation therapy in patients with Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) with unmutated IGHV (uIGHV).
Conditions
- Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
Interventions
SurovatamigDrug
Surovatamig will be administered as a subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DOSRI- Number of participants with adverse events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 5 years
- Phase III- Progression Free Survival (PFS)Time frame: Until disease progression or death (up to 5 years)
- DOSRI- Number of participants with study intervention discontinuations, dose reductions and dose delays due to AEsTime frame: Up to 5 years
Locations
44 sites in 5 countries. Site status is shown where the registry gives one.
Research Site
La Jolla, California · Not yet recruiting
Research Site
Denver, Colorado · Not yet recruiting
Research Site
New Haven, Connecticut · Not yet recruiting
Research Site
Chicago, Illinois · Not yet recruiting
Research Site
Kansas City, Kansas · Not yet recruiting
Research Site
Louisville, Kentucky · Not yet recruiting
Research Site
Bethesda, Maryland · Not yet recruiting
Research Site
Boston, Massachusetts · Not yet recruiting
Research Site
Rochester, Minnesota · Not yet recruiting
Research Site
Basking Ridge, New Jersey · Not yet recruiting
Research Site
Rochester, New York · Not yet recruiting
Research Site
Cleveland, Ohio · Not yet recruiting
Research Site
Pittsburgh, Pennsylvania · Not yet recruiting
Research Site
Houston, Texas · Not yet recruiting
Research Site
Adelaide, Australia · Recruiting
Research Site
Fitzroy, Australia · Not yet recruiting
Research Site
Heidelberg, Australia · Recruiting
Research Site
Nedlands, Australia · Recruiting
Research Site
Perth, Australia · Recruiting
Research Site
Rockingham, Australia · Not yet recruiting
Research Site
Calgary, Alberta, Canada · Recruiting
Research Site
Vancouver, British Columbia, Canada · Suspended
Research Site
Halifax, Nova Scotia, Canada · Recruiting
Research Site
Hamilton, Ontario, Canada · Not yet recruiting
Research Site
Toronto, Ontario, Canada · Recruiting
Research Site
Montreal, Quebec, Canada · Suspended
Research Site
Montreal, Quebec, Canada · Recruiting
Research Site
Québec, Quebec, Canada · Suspended
Research Site
Adapazarı, Turkey (Türkiye) · Recruiting
Research Site
Antalya, Turkey (Türkiye) · Recruiting
Research Site
Istanbul, Turkey (Türkiye) · Not yet recruiting
Research Site
Istanbul, Turkey (Türkiye) · Recruiting
Research Site
Istanbul, Turkey (Türkiye) · Recruiting
Research Site
Kocaeli, Turkey (Türkiye) · Recruiting
Research Site
Mezitli, Turkey (Türkiye) · Recruiting
Research Site
Edinburgh, United Kingdom · Recruiting
Research Site
Hampshire, United Kingdom · Recruiting
Research Site
Leeds, United Kingdom · Not yet recruiting
Research Site
London, United Kingdom · Recruiting
Research Site
London, United Kingdom · Recruiting
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.